Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1956 1
1959 1
1960 2
1961 5
1962 1
1963 5
1964 5
1965 5
1966 2
1967 5
1968 4
1969 2
1970 8
1971 2
1972 2
1973 6
1974 5
1975 6
1976 10
1977 9
1978 5
1979 7
1980 11
1981 13
1982 6
1983 12
1984 13
1985 16
1986 17
1987 7
1988 15
1989 8
1990 6
1991 8
1992 11
1993 13
1994 15
1995 14
1996 24
1997 13
1998 27
1999 26
2000 28
2001 20
2002 14
2003 20
2004 21
2005 22
2006 26
2007 40
2008 29
2009 36
2010 38
2011 37
2012 53
2013 51
2014 55
2015 61
2016 68
2017 74
2018 76
2019 97
2020 103
2021 113
2022 95
2023 80
2024 87
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,524 results

Results by year

Filters applied: . Clear all
Page 1
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leal TA, Riess JW, Jensen E, Zhao B, Pietanza MC, Brahmer JR. Reck M, et al. Among authors: hotta k. J Clin Oncol. 2021 Jul 20;39(21):2339-2349. doi: 10.1200/JCO.21.00174. Epub 2021 Apr 19. J Clin Oncol. 2021. PMID: 33872070 Free PMC article. Clinical Trial.
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.
Hotta K, Hida T, Nokihara H, Morise M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Yoshimoto T, Takata S, Tamura T. Hotta K, et al. ESMO Open. 2022 Aug;7(4):100527. doi: 10.1016/j.esmoop.2022.100527. Epub 2022 Jul 14. ESMO Open. 2022. PMID: 35843080 Free PMC article. Clinical Trial.
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T. Hida T, et al. Among authors: hotta k. Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10. Lancet. 2017. PMID: 28501140 Clinical Trial.
Echinomycin biosynthesis.
Sato M, Nakazawa T, Tsunematsu Y, Hotta K, Watanabe K. Sato M, et al. Among authors: hotta k. Curr Opin Chem Biol. 2013 Aug;17(4):537-45. doi: 10.1016/j.cbpa.2013.06.022. Epub 2013 Jul 12. Curr Opin Chem Biol. 2013. PMID: 23856054 Review.
Comprehensive Analysis of Early-onset Colorectal Cancer: A Review.
Takada K, Hotta K, Kishida Y, Ito S, Imai K, Ono H. Takada K, et al. Among authors: hotta k. J Anus Rectum Colon. 2023 Oct 25;7(4):241-249. doi: 10.23922/jarc.2023-032. eCollection 2023. J Anus Rectum Colon. 2023. PMID: 37900694 Free PMC article. Review.
Nomogram as a novel predictive tool for lymph node metastasis in T1 colorectal cancer treated with endoscopic resection: a nationwide, multicenter study.
Kajiwara Y, Oka S, Tanaka S, Nakamura T, Saito S, Fukunaga Y, Takamatsu M, Kawachi H, Hotta K, Ikematsu H, Kojima M, Saito Y, Yamada M, Kanemitsu Y, Sekine S, Nagata S, Yamada K, Kobayashi N, Ishihara S, Saitoh Y, Matsuda K, Togashi K, Komori K, Ishiguro M, Kuwai T, Okuyama T, Ohuchi A, Ohnuma S, Sakamoto K, Sugai T, Katsumata K, Matsushita HO, Yamano HO, Eda H, Uraoka T, Akimoto N, Kobayashi H, Ajioka Y, Sugihara K, Ueno H. Kajiwara Y, et al. Among authors: hotta k. Gastrointest Endosc. 2023 Jun;97(6):1119-1128.e5. doi: 10.1016/j.gie.2023.01.022. Epub 2023 Jan 18. Gastrointest Endosc. 2023. PMID: 36669574 Free article.
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Nishio M, Ohe Y, Ikeda S, Yokoyama T, Hayashi H, Fukuhara T, Sato Y, Tanaka H, Hotta K, Sugawara S, Daga H, Okamoto I, Kasahara K, Naito T, Li L, Gupta RG, Bushong J, Mizutani H. Nishio M, et al. Among authors: hotta k. Int J Clin Oncol. 2023 Oct;28(10):1354-1368. doi: 10.1007/s10147-023-02390-2. Epub 2023 Aug 7. Int J Clin Oncol. 2023. PMID: 37548831 Free PMC article. Clinical Trial.
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.
Paz-Ares L, Garassino MC, Chen Y, Reinmuth N, Hotta K, Poltoratskiy A, Trukhin D, Hochmair MJ, Özgüroğlu M, Ji JH, Statsenko G, Conev N, Bondarenko I, Havel L, Losonczy G, Xie M, Lai Z, Godin-Heymann N, Mann H, Jiang H, Shrestha Y, Goldman JW. Paz-Ares L, et al. Among authors: hotta k. Clin Cancer Res. 2024 Feb 16;30(4):824-835. doi: 10.1158/1078-0432.CCR-23-1689. Clin Cancer Res. 2024. PMID: 37801329 Free PMC article. Clinical Trial.
Transient mixed chimerism for allograft tolerance.
Oura T, Hotta K, Cosimi AB, Kawai T. Oura T, et al. Among authors: hotta k. Chimerism. 2015 Apr 3;6(1-2):21-6. doi: 10.1080/19381956.2015.1111975. Epub 2015 Oct 30. Chimerism. 2015. PMID: 26517761 Free PMC article. Review.
1,524 results